AI Governance for Biotech Executives

Frameworks, risk committees, board oversight models, and compliance structures for responsible AI deployment in biotech organizations.

AI vendor due diligence for biotech executives: what to ask before you buy

AI vendor due diligence for biotech executives: what to ask before you buy

AI vendor due diligence for biotech executives: what to ask before you buy Most biotech executives are receiving at least one AI vendor pitch every week. The tools range from genuinely useful to actively risky, and the marketing language is nearly identical across the spectrum. Very few executives have a structured framework for deciding which […]

AI vendor due diligence for biotech executives: what to ask before you buy Read More »

AI in biotech talent acquisition: how to hire faster without lowering the bar

AI in biotech talent acquisition: how to hire faster without lowering the bar

AI in biotech talent acquisition: how to hire faster without lowering the bar Anthropic paid over $400 million for a team of fewer than 10 computational biologists this week. That works out to approximately $40 million per person. That is the talent market biotech companies are competing in when they try to hire AI-specialist roles

AI in biotech talent acquisition: how to hire faster without lowering the bar Read More »

Anthropic acquires Coefficient Bio for $400M: what it means for AI drug discovery

Anthropic acquires Coefficient Bio for $400M: what it means for AI drug discovery

Anthropic acquires Coefficient Bio for $400M: what it means for AI drug discovery Anthropic has acquired Coefficient Bio, an AI biotech startup with fewer than 10 employees, for over $400 million in stock. The company had been operating in stealth for just eight months. It had no publicly disclosed product and no commercial revenue. The

Anthropic acquires Coefficient Bio for $400M: what it means for AI drug discovery Read More »

Dark cinematic banner showing a professional at a desk with AI data visualisation and electric blue teal accents representing personal AI productivity

AI Is Not Just a Work Tool. It Is a Personal Competitive Weapon.

Some pharma and biotech professionals are gaining 5 hours a week using personal AI setups at home to prepare for meetings, sharpen decisions, and outpace colleagues. This article explains the generational anxiety driving AI avoidance, why experience is still an advantage when paired with AI, and what a practical personal AI setup looks like for professionals who want to get ahead.

AI Is Not Just a Work Tool. It Is a Personal Competitive Weapon. Read More »

Dark cinematic banner with electric blue data grid and teal accents representing AI governance in a pharma office setting

AI for Pharma Office Workers: The Compliant Path Forward

Pharma and biotech office workers are losing productivity to blanket AI bans while IT offers only one approved tool. This article defines the real data risk boundary, identifies compliant enterprise AI tools including Microsoft 365 Copilot, Veeva AI, and Azure OpenAI, and outlines a four-step path forward for organisations ready to move beyond restriction and into governed AI enablement.

AI for Pharma Office Workers: The Compliant Path Forward Read More »